CCT007093 and the Logic of PPM1D Signaling
2026-09-24
CCT007093 is a PPM1D inhibitor that helps researchers examine how phosphatase control shapes p38 MAPK signaling and cell fate. This article focuses on interpreting evidence across renal injury and cancer models, with particular attention to what the experiments can—and cannot—establish.
Anlotinib hydrochloride Assay Workflows
2026-09-23
Build a mechanism-led angiogenesis workflow around VEGFR2, PDGFRβ, FGFR1, and ERK readouts. This guide connects endothelial migration and tube formation assays with practical controls, concentration selection, troubleshooting, and comparative cancer research applications.
GSK621 Workflows for AML and AMPK Research
2026-09-22
GSK621 is a potent AMPK agonist for connecting energy sensing with AML proliferation, apoptosis, autophagy, and lipid metabolism. This workflow-focused guide covers stock preparation, phospho-AMPK assay design, macrophage immunometabolism, comparative controls, and troubleshooting.
Metal-Free Carbon Nanozymes for ALP Detection
2026-09-21
The reference study develops a metal-free carbon-dot nanozyme assay in which alkaline phosphatase hydrolysis of pyrophosphate releases nanozyme activity and produces a colorimetric turn-on signal. Kinetic analysis identifies pyrophosphate as a noncompetitive inhibitor at a binding site distinct from the principal catalytic site, supporting sensitive ALP measurement while reducing metal-ion-related interference.
Neuritin, ER Stress, and NF-κB After SAH
2026-09-21
The reference study shows that endoplasmic reticulum stress-related inflammatory pathways converge on NF-κB to connect neuroinflammation with neuronal apoptosis during early brain injury after subarachnoid hemorrhage. Neuritin overexpression suppresses the IRE1α-TRAF2-NF-κB, PERK-eIF2α-NF-κB, and ATF6-AKT-NF-κB routes, providing a mechanistic framework for evaluating neuroprotection.
Dye Models for Small Biopsy Handling
2026-09-20
The reference study evaluates whether tissue marking dyes can improve the visibility and retention of very small biopsy fragments during routine surgical pathology processing. Its central practical finding is that hematoxylin provided the most suitable balance of visibility, low toxicity, and minimal interference, while crystal violet was investigated but was not selected as the preferred marker.
Isoliensinine, Lipid Droplets, and MAFLD Fibrosis
2026-09-19
The reference study identifies a TRPV1–AMPK/ACC mechanism through which isoliensinine from Plumula Nelumbinis restores lipid droplets in hepatic stellate cells and attenuates MAFLD-associated fibrosis. Its combined animal, LX2-cell, molecular, and imaging evidence provides a mechanistic framework linking calcium homeostasis to stellate-cell metabolic state, while also highlighting important limits for clinical translation.
Phosphatase Inhibitor Cocktail 1: Assay Logic
2026-09-19
Phosphatase Inhibitor Cocktail 1 helps distinguish true signaling biology from sample-preparation artifacts. This guide connects phosphorylation state preservation to HCMV–AKT research, assay selection, and practical workflow controls.
Ouabain: From Pump Inhibition to Senolytic Assays
2026-09-18
Ouabain is a selective Na+/K+-ATPase inhibitor that links ion-gradient control to calcium signaling, cardiovascular physiology, and emerging senolytic research. This guide focuses on assay interpretation, experimental controls, and how machine-learning-derived senolytic evidence can sharpen Ouabain study design.
Lactate as a Metabolic–Immune Control Point
2026-09-18
Lactate is more than a glycolytic by-product: it is a measurable metabolic output, a redox-linked carbon source, and a signaling variable that can reshape tumor immunity. This thought-leadership article translates the NAT1–ENO1–lactate–PD-L1 mechanism in colorectal cancer into practical guidance for assay design, biomarker development, and translational strategy.
Annular Microneedles for Glaucoma Mitochondrial Therapy
2026-09-17
A 2026 Biomaterials study combines Nmnat1 gene delivery, nicotinamide supplementation, and an annular sector microneedle to target mitochondrial dysfunction in the trabecular meshwork. The approach improved local cargo delivery, reduced intraocular pressure, and alleviated fibrosis in cellular and dexamethasone-induced mouse models, while leaving important translational questions unresolved.
AZD8055: Practical mTOR Inhibitor Workflow
2026-09-17
AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 signaling, mTORC2 signaling, cancer cell proliferation, and metabolism. This dossier-based guide supports preparation, assay setup, and QC, but the compound should not be used as stand-alone evidence of clinical efficacy or as an aqueous formulation without additional development.
Alosetron and the Intestinal Signaling Frontier
2026-09-16
Alosetron offers a selective receptor-level perturbation for connecting serotonin biology with intestinal motility, visceral pain, epithelial polarity, and stem-cell fate. This thought-leadership article places the compound alongside the CDC42–YAP–EGFR–mTOR framework, distinguishing established findings from testable translational hypotheses.
Clarithromycin CYP3A Inhibitor Workflow
2026-09-15
Build reproducible CYP3A inhibition assays with Clarithromycin SKU A4322, from solvent handling and controls to LC-MS interpretation. The workflow also shows how a CYP-independent anticoagulant reference model can sharpen drug-drug interaction research without overstating translational evidence.
Helper Lipids in Self-Amplifying RNA Nanoparticles
2026-09-15
Barbieri et al. systematically examined how helper-lipid identity interacts with ionisable lipids to control self-amplifying RNA nanoparticle potency, immunogenicity, and storage stability. The study identifies C12–200 combined with DSPC as a strong formulation balance, while showing that cell-culture expression alone does not reliably predict ex vivo or in vivo performance.